In Conversation

Fernando Fogarin – Strategic Project Lead Emerging Markets, Organon

Fernando Fogarin – Strategic Project Lead Emerging Markets, Organon

By addressing women's health, we positively impact the entire community. A healthy, empowered woman leads to a resilient family and a stronger society
Yu Wang – Chairman, Chinese Foundation for Hepatitis Prevention & Control

Yu Wang – Chairman, Chinese Foundation for Hepatitis Prevention & Control

The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth
Walid Tohme – Partner, Strategy& Middle East, PwC

Walid Tohme – Partner, Strategy& Middle East, PwC

Aligning multiple stakeholders in Saudi Arabia's healthcare transformation is pivotal yet challenging. With the creation of new entities alongside the transformation of existing ones, establishing cohesive governance and operational models becomes crucial
Diana Liu – General Manager, Roche Hong Kong & Macau

Diana Liu – General Manager, Roche Hong Kong & Macau

These three elements—expertise, quality, and efficiency—make Hong Kong a unique and valuable location for our clinical trials
Sabrina Chan – Senior Executive Director, Hong Kong Association of the Pharmaceutical Industry (HKAPI)

Sabrina Chan – Senior Executive Director, Hong Kong Association of the Pharmaceutical Industry (HKAPI)

What is critical here is to ensure Hong Kong's regulatory framework remains aligned with international standards and being recognized by many markets
Lionel Collet – President, Haute Autorité de Santé (HAS), France

Lionel Collet – President, Haute Autorité de Santé (HAS), France

Maintaining independence is paramount because we must never be beholden, in any way, to either industry interests or governmental influence.
Mohammed Khalil – CEO, SAJA Pharmaceuticals

Mohammed Khalil – CEO, SAJA Pharmaceuticals

Our goal is to ensure that the right medication is available at the right time and at a fair price
Sarah McMullen, Country Director, FDA India Office

Sarah McMullen, Country Director, FDA India Office

As the saying goes – “a rising tide lifts all boats”, and we would expect that universal implementation of GMPs would buoy product quality among those firms in compliance
Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)

Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)

The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of blue-sky research, exemplified by important contributions to critical advancements like RNA vaccines, there has not been a corresponding increase in funding
See more

In Case You Missed It

InFigures

The top 10 Indian pharma companies ranked by market capitalization as of June 2023, compiled by Global Data. Way out in front is Sun Pharma, followed by Dr Reddy’s and Cipla. Made with Visme Infographic Maker

As Big Pharma makes evermore declarations on its sustainability credentials, who are the industry’s most sustainable companies? With wildlife under severe threat from biopharmaceutical run-off, which companies are truly dedicated to change? Which are truly dedicated to equitable pay structures and promoting diversity, equity and inclusion? To answer these questions, the Toronto-based media and research…

Latin America will be the world’s fastest growing region for pharmaceuticals up to 2027, with a stunning expected compound annual growth rate of 22 percent, according to recent reporting from IQVIA. The Indian subcontinent can also expect sizeable growth over the next three years, although the US, Europe, and East Asia will remain the largest…

The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here